MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
Moderna, Inc. (NASDAQ:MRNA)*
*Key People: Moderna
Parents
*Key People: Industry
Moderna, Inc. (NASDAQ:MRNA)*
Children
2022: Timothy Springer, PhD, Overall rank: 1,445 (tied) Net worth in 2022: $2.1 billion , Net worth in 2021: $2.2 billion Dr. Springer is an immunologist and professor of biological chemistry and molecular pharmacology at Boston-based Harvard Medical School and an investor in biotech and pharmaceutical companies. When Moderna Therapeutics launched its initial public offering in 2018, Dr. Springer became the company's fourth-largest shareholder.
2025: Moderna lays off 10% of workforce in further cost-cutting move
Brice Challamel VP, AI Products & Platforms Moderna (2025)
Clinical Trial Diversity, Moderna (2021)
Co-founder of MRNA, Noubar Afeyan, has an enviable track record of bringing forth innovative companies and selling them off once its core product is proven.
Flagship VentureLabsTM co-founded moderna Therapeutics with world-leading academic researchers Robert Langer and Kenneth Chien
Founders: Robert S. Langer, Derrick Rossi, Kenneth R. Chien, Noubar Afeyan
Jameka Hill, Director, Patient Engagement & Advocacy
moderna’s technology platform, invented by Assistant Professor Derrick Rossi of Harvard, also a company co-founder, makes it possible to direct cells to express proteins without changing their genome or creating long term safety concerns.
No. of employees: 1,100 (2021)
Stéphane Bancel Moderna CEO (2020)
Stephen Hoge, President, Moderna, former, SVP corporate development, Moderna, CEO, Onkaido. (2026)
Wade Davis, vice president of computational science, Moderna (2025)
Jumps
Finance & Acquisitions: Moderna
Organization & Developments: Moderna